{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T02:41:39Z","timestamp":1777344099586,"version":"3.51.4"},"reference-count":29,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,4,29]],"date-time":"2023-04-29T00:00:00Z","timestamp":1682726400000},"content-version":"vor","delay-in-days":28,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["phiro.science","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Physics and Imaging in Radiation Oncology"],"published-print":{"date-parts":[[2023,4]]},"DOI":"10.1016\/j.phro.2023.100445","type":"journal-article","created":{"date-parts":[[2023,5,4]],"date-time":"2023-05-04T02:49:47Z","timestamp":1683168587000},"page":"100445","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"special_numbering":"C","title":["Treatment planning comparison of high-dose-rate brachytherapy vs. robotic and conventional stereotactic body radiotherapy for ultrahypofractionated treatment of prostate cancer"],"prefix":"10.1016","volume":"26","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1225-2910","authenticated-orcid":false,"given":"Yasuo","family":"Yoshioka","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazuma","family":"Sasamura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7733-1594","authenticated-orcid":false,"given":"Makoto","family":"Ito","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5845-238X","authenticated-orcid":false,"given":"Masahiro","family":"Kaneko","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6006-1890","authenticated-orcid":false,"given":"Taro","family":"Takahashi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wataru","family":"Anno","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nana","family":"Shimoyachi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0725-2561","authenticated-orcid":false,"given":"Junji","family":"Suzuki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2543-9584","authenticated-orcid":false,"given":"Takahito","family":"Okuda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2471-605X","authenticated-orcid":false,"given":"Tairo","family":"Kashihara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Koji","family":"Inaba","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7817-624X","authenticated-orcid":false,"given":"Hiroshi","family":"Igaki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1579-7406","authenticated-orcid":false,"given":"Jun","family":"Itami","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.phro.2023.100445_b0005","unstructured":"National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology (NCCN guidelines\u00ae). Prostate Cancer. Version 4.2022. https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/prostate.pdf. Accessed on July 1, 2022."},{"key":"10.1016\/j.phro.2023.100445_b0010","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1038\/nrurol.2017.76","article-title":"The evolution of brachytherapy for prostate cancer","volume":"14","author":"Zaorsky","year":"2017","journal-title":"Nat Rev Urol"},{"key":"10.1016\/j.phro.2023.100445_b0015","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1016\/S0360-3016(00)00687-8","article-title":"High-dose-rate interstitial brachytherapy as a monotherapy for localized prostate cancer: treatment description and preliminary results of a phase I\/II clinical trial","volume":"48","author":"Yoshioka","year":"2000","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.phro.2023.100445_b0020","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1016\/j.ijrobp.2015.07.2290","article-title":"High-dose-rate monotherapy for localized prostate cancer: 10-year results","volume":"94","author":"Hauswald","year":"2016","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.phro.2023.100445_b0025","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/S0360-3016(00)01463-2","article-title":"Phase II prospective study of the use of conformal high-dose-rate brachytherapy as monotherapy for the treatment of favorable stage prostate cancer: a feasibility report","volume":"49","author":"Martinez","year":"2001","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.phro.2023.100445_b0030","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1016\/j.ijrobp.2012.07.004","article-title":"High-dose-rate interstitial brachytherapy as monotherapy for clinically localized prostate cancer: treatment evolution and mature results","volume":"85","author":"Zamboglou","year":"2013","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.phro.2023.100445_b0035","doi-asserted-by":"crossref","first-page":"1376","DOI":"10.1016\/j.ijrobp.2011.04.031","article-title":"High-dose-rate brachytherapy alone for localized prostate cancer in patients at moderate or high risk of biochemical recurrence","volume":"82","author":"Hoskin","year":"2012","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.phro.2023.100445_b0040","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/j.radonc.2020.02.009","article-title":"Prostate high dose-rate brachytherapy as monotherapy for low and intermediate risk prostate cancer: efficacy results from a randomized phase II clinical trial of one fraction of 19 Gy or two fractions of 13.5 Gy","volume":"146","author":"Morton","year":"2020","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.phro.2023.100445_b0045","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1016\/j.prro.2018.08.002","article-title":"Hypofractionated radiation therapy for localized prostate cancer: executive summary of an ASTRO, ASCO, and AUA evidence-based guideline","volume":"8","author":"Morgan","year":"2018","journal-title":"Pract Radiat Oncol"},{"key":"10.1016\/j.phro.2023.100445_b0050","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1016\/S1470-2045(16)30102-4","article-title":"Conventional versus hypofractionated high-dose intensity-modulated radiotherapy for prostate cancer: 5-year outcomes of the randomised, non-inferiority, phase 3 CHHiP trial","volume":"17","author":"Dearnaley","year":"2016","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.phro.2023.100445_b0055","doi-asserted-by":"crossref","first-page":"2325","DOI":"10.1200\/JCO.2016.67.0448","article-title":"Randomized phase III noninferiority study comparing two radiotherapy fractionation schedules in patients with low-risk prostate cancer","volume":"34","author":"Lee","year":"2016","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.phro.2023.100445_b0060","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1016\/S0140-6736(19)31131-6","article-title":"Ultra-hypofractionated versus conventionally fractionated radiotherapy for prostate cancer: 5-year outcomes of the HYPO-RT-PC randomised, non-inferiority, phase 3 trial","volume":"394","author":"Widmark","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.phro.2023.100445_b0065","doi-asserted-by":"crossref","first-page":"1531","DOI":"10.1016\/S1470-2045(19)30569-8","article-title":"Intensity-modulated fractionated radiotherapy versus stereotactic body radiotherapy for prostate cancer (PACE-B): acute toxicity findings from an international, randomised, open-label, phase 3, non-inferiority trial","volume":"20","author":"Brand","year":"2019","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.phro.2023.100445_b0070","doi-asserted-by":"crossref","first-page":"1588","DOI":"10.1016\/j.ijrobp.2007.11.067","article-title":"Virtual HDR CyberKnife treatment for localized prostatic carcinoma: dosimetry comparison with HDR brachytherapy and preliminary clinical observations","volume":"70","author":"Fuller","year":"2008","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.phro.2023.100445_b0075","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.brachy.2020.07.011","article-title":"Real-world dosimetric comparison between CyberKnife SBRT and HDR brachytherapy for the treatment of prostate cancer","volume":"20","author":"Chatzikonstantinou","year":"2021","journal-title":"Brachytherapy"},{"key":"10.1016\/j.phro.2023.100445_b0080","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1016\/j.brachy.2013.03.003","article-title":"A comparative dosimetric analysis of virtual stereotactic body radiotherapy to high-dose-rate monotherapy for intermediate-risk prostate cancer","volume":"12","author":"Spratt","year":"2013","journal-title":"Brachytherapy"},{"key":"10.1016\/j.phro.2023.100445_b0085","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1093\/jjco\/hyab094","article-title":"Stereotactic body radiation therapy for Japanese patients with localized prostate cancer: 2-year results and predictive factors for acute genitourinary toxicities","volume":"51","author":"Ito","year":"2021","journal-title":"Jpn J Clin Oncol"},{"key":"10.1016\/j.phro.2023.100445_b0090","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1016\/j.ijrobp.2015.05.044","article-title":"High-dose-rate brachytherapy as monotherapy for intermediate- and high-risk prostate cancer: clinical results for a median 8-year follow-up","volume":"94","author":"Yoshioka","year":"2016","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.phro.2023.100445_b0095","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1093\/jjco\/hyab167","article-title":"Outcomes of intensity-modulated radiation therapy for intermediate- or high-risk prostate cancer: a single-institutional study","volume":"52","author":"Sasamura","year":"2022","journal-title":"Jpn J Clin Oncol"},{"key":"10.1016\/j.phro.2023.100445_b0100","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.radonc.2022.02.007","article-title":"Two-fraction stereotactic ablative radiotherapy (SABR) versus two-fraction high dose rate (HDR) brachytherapy for localized prostate cancer: does dose heterogeneity matter?","volume":"169","author":"Correa","year":"2022","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.phro.2023.100445_b0105","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1200\/JCO.20.02873","article-title":"Focal boost to the intraprostatic tumor in external beam radiotherapy for patients with localized prostate cancer: results from the FLAME randomized phase III trial","volume":"39","author":"Kerkmeijer","year":"2021","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.phro.2023.100445_b0110","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1016\/j.ijrobp.2014.07.017","article-title":"National Cancer Data Base analysis of radiation therapy consolidation modality for cervical cancer: the impact of new technological advancements","volume":"90","author":"Gill","year":"2014","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.phro.2023.100445_b0115","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1016\/j.ijrobp.2016.12.024","article-title":"Continued benefit to rectal separation for prostate radiation therapy: final results of a phase III trial","volume":"97","author":"Hamstra","year":"2017","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.phro.2023.100445_b0120","first-page":"16","article-title":"Planning feasibility of extremely hypofractionated prostate radiotherapy on a 1.5 T magnetic resonance imaging guided linear accelerator. Phys Imaging","volume":"11","author":"den Hartogh","year":"2019","journal-title":"Radiat Oncol"},{"key":"10.1016\/j.phro.2023.100445_b0125","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.phro.2019.02.002","article-title":"Clinical implementation of magnetic resonance imaging guided adaptive radiotherapy for localized prostate cancer","volume":"9","author":"Tetar","year":"2019","journal-title":"Phys Imaging Radiat Oncol"},{"key":"10.1016\/j.phro.2023.100445_b0130","first-page":"20","article-title":"Online adaptive planning for prostate stereotactic body radiotherapy using a 1.5 Tesla magnetic resonance imaging-guided linear accelerator. Phys Imaging","volume":"17","author":"Yang","year":"2021","journal-title":"Radiat Oncol"},{"key":"10.1016\/j.phro.2023.100445_b0135","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.phro.2020.07.006","article-title":"Focal salvage treatment for radiorecurrent prostate cancer: A magnetic resonance-guided stereotactic body radiotherapy versus high-dose-rate brachytherapy planning study","volume":"15","author":"Willigenburg","year":"2020","journal-title":"Phys Imaging Radiat Oncol"},{"key":"10.1016\/j.phro.2023.100445_b0140","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1097\/COC.0000000000000311","article-title":"A pooled analysis of biochemical failure in intermediate-risk prostate cancer following definitive stereotactic body radiotherapy (SBRT) or high-dose-rate brachytherapy (HDR-B) monotherapy","volume":"41","author":"Hegde","year":"2018","journal-title":"Am J Clin Oncol"},{"key":"10.1016\/j.phro.2023.100445_b0145","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1016\/j.radonc.2021.02.028","article-title":"Ultra-hypofractionated radiotherapy for low- and intermediate risk prostate cancer: high-dose-rate brachytherapy vs stereotactic ablative radiotherapy","volume":"158","author":"Tsang","year":"2021","journal-title":"Radiother Oncol"}],"container-title":["Physics and Imaging in Radiation Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2405631623000362?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2405631623000362?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T08:15:40Z","timestamp":1762503340000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2405631623000362"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4]]},"references-count":29,"alternative-id":["S2405631623000362"],"URL":"https:\/\/doi.org\/10.1016\/j.phro.2023.100445","relation":{},"ISSN":["2405-6316"],"issn-type":[{"value":"2405-6316","type":"print"}],"subject":[],"published":{"date-parts":[[2023,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Treatment planning comparison of high-dose-rate brachytherapy vs. robotic and conventional stereotactic body radiotherapy for ultrahypofractionated treatment of prostate cancer","name":"articletitle","label":"Article Title"},{"value":"Physics and Imaging in Radiation Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.phro.2023.100445","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Author(s). Published by Elsevier B.V. on behalf of European Society of Radiotherapy & Oncology.","name":"copyright","label":"Copyright"}],"article-number":"100445"}}